Cargando…

Treatment and Prevention of Bleeds in Haemophilia Patients with Inhibitors to Factor VIII/IX

The development of alloantibodies neutralising therapeutically administered factor (F) VIII/IX (inhibitors) is currently the most severe complication of the treatment of haemophilia. When persistent and at a high titre, inhibitors preclude the standard replacement treatment with FVIII/FIX concentrat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rocino, Angiola, Franchini, Massimo, Coppola, Antonio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5406778/ https://www.ncbi.nlm.nih.gov/pubmed/28420167 http://dx.doi.org/10.3390/jcm6040046

Ejemplares similares

Italian experience with rVIII-single chain: a survey of patients with haemophilia A and their physicians
por: Borchiellini, Alessandra, et al.
Publicado: (2021)

Recombinant factor VIII Fc for the treatment of haemophilia A
por: Hermans, Cedric, et al.
Publicado: (2021)

The evolution of factor VIIa in the treatment of bleeding in haemophilia with inhibitors
por: Meeks, Shannon L., et al.
Publicado: (2019)

Factor VIII companion diagnostic for haemophilia
por: Hu, Chunxiao, et al.
Publicado: (2022)

Diagnosis and treatment of chronic synovitis in patients with haemophilia: consensus statements from the Italian Association of Haemophilia Centres
por: Di Minno, Matteo Nicola Dario, et al.
Publicado: (2021)

Comparison of Bypassing Agents in Bleeding Reduction in Treatment of Bleeding Episodes in Patients With Haemophilia and Inhibitors
por: Golestani, Mina, et al.
Publicado: (2014)

Bleeding pattern and consumption of factor VIII concentrate in adult patients with haemophilia A without inhibitors in the Czech Republic between 2013 and 2021 (Czech National Haemophilia Programme registry data)
por: Romanová, Gabriela, et al.
Publicado: (2023)

Biological mechanisms underlying inter‐individual variation in factor VIII clearance in haemophilia
por: Turecek, Peter L., et al.
Publicado: (2020)

Physical activity in individuals with haemophilia and experience with recombinant factor VIII Fc fusion protein and recombinant factor IX Fc fusion protein for the treatment of active patients: a literature review and case reports
por: Wang, Michael, et al.
Publicado: (2016)

Modified Factor VIII and Factor IX recombinant products
por: Santagostino, Elena, et al.
Publicado: (2018)

Inhibitors in haemophilia A and B: Management of bleeds, inhibitor eradication and strategies for difficult‐to‐treat patients
por: Ljung, Rolf, et al.
Publicado: (2018)

Successful Long Term Eradication of Factor VIII Inhibitor in Patients with Acquired Haemophilia A in Saudi Arabia
por: Zaher, Galila, et al.
Publicado: (2012)

Successful transfemoral prosthesis in a patient with haemophilia A and factor VIII inhibitors: A case report
por: Chao, Ta-Chung, et al.
Publicado: (2023)

Impact of extreme weight loss on factor VIII concentrate pharmacokinetics in haemophilia
por: van Moort, Iris, et al.
Publicado: (2021)

Factor VIII and Factor IX Activity Measurements for Hemophilia Diagnosis and Related Treatments
por: Bowyer, Annette E., et al.
Publicado: (2022)

Updates in clinical trial data of extended half-life recombinant factor IX products for the treatment of haemophilia B
por: Mahlangu, Johnny N.
Publicado: (2018)

Treatment of hemophilia B: focus on recombinant factor IX
por: Franchini, Massimo, et al.
Publicado: (2013)

Real-World Utilisation and Bleed Rates in Patients with Haemophilia B Who Switched to Recombinant Factor IX Fusion Protein (rIX-FP): A Retrospective International Analysis
por: Hermans, Cedric, et al.
Publicado: (2020)

Zero incidence of factor VIII inhibitors and successful haemostatic response in previously factor VIII‐treated patients with haemophilia A switching to turoctocog alfa in a noninterventional study
por: Escuriola Ettingshausen, Carmen, et al.
Publicado: (2021)

Patient preference for needleless factor VIII reconstitution device: the Italian experience
por: Musso, Roberto, et al.
Publicado: (2010)

Augmented Degradation of Factors VIII and IX in the Intermittent Movement State
por: Cohen, Haim, et al.
Publicado: (2023)

Surgical outcomes in patients with haemophilia A or B receiving extended half‐life recombinant factor VIII and IX Fc fusion proteins: Real‐world experience in the Nordic countries
por: Lehtinen, Anna‐Elina, et al.
Publicado: (2022)

Acquired Factor VIII Inhibitor Presenting as Occult GI Bleeding
por: Pacheco Cano, Carlos I., et al.
Publicado: (2018)

Issues in pediatric haemophilia care
por: Giordano, Paola, et al.
Publicado: (2013)

Concurrent acquired inhibitors to factor VIII and IX, a laboratory artifact: a case report
por: Doma, Saša Anžej, et al.
Publicado: (2016)

Long-term treatment course of a patient with mild haemophilia A who developed a high titre factor VIII inhibitor
por: Iioka, F, et al.
Publicado: (2014)

PB2655: EVALUATION OF THE EFFICACY AND SAFETY IMMUNOSUPPRESSIVE THERAPY IN PATIENTS WITH ACQUIRED FACTOR VIII AND IX INHIBITOR
por: Koyun, Derya, et al.
Publicado: (2023)

Identification of a novel mutation in the factor VIII gene causing severe haemophilia A
por: Nissen, S. K., et al.
Publicado: (2018)

Area under the curve: Comparing the value of factor VIII replacement therapies in haemophilia A
por: Persson, Sofie, et al.
Publicado: (2022)

Ex vivo factor VIII‐modified proliferating human hepatocytes therapy for haemophilia A
por: Zhang, Kun, et al.
Publicado: (2023)

Switching treatments in haemophilia: is there a risk of inhibitor development?
por: Santagostino, Elena, et al.
Publicado: (2015)

Osteoporosis management and falls prevention in patients with haemophilia: Review of haemophilia guidelines
por: Petkovic, Madison J., et al.
Publicado: (2022)

Sustained high trough factor IX activity levels with continued use of rIX‐FP in adult and paediatric patients with haemophilia B
por: Gill, Joan C., et al.
Publicado: (2019)

Real-World Rates of Bleeding, Factor VIII Use, and Quality of Life in Individuals with Severe Haemophilia A Receiving Prophylaxis in a Prospective, Noninterventional Study
por: Kenet, Gili, et al.
Publicado: (2021)

Postmarketing safety and effectiveness of recombinant factor IX (nonacog alfa) in Japanese patients with haemophilia B
por: Fukutake, Katsuyuki, et al.
Publicado: (2019)

Platelet-targeted gene therapy with human factor VIII establishes haemostasis in dogs with haemophilia A
por: Du, Lily M., et al.
Publicado: (2013)

Clinical Application of Factor VIII:C to VWF:Ag Ratio for the Screening of Haemophilia A Carriers
por: Yoo, Ki-Young, et al.
Publicado: (2022)

Efficacy of Corticosteroids Alone in the Eradication of Factor VIII Inhibitor in an Old Female with Idiopathic Acquired Haemophilia A: Description of a Case
por: Girelli, Francesco, et al.
Publicado: (2012)

Cost‐effectiveness of recombinant factor VIII Fc versus emicizumab for prophylaxis in adults and adolescents with haemophilia A without inhibitors in the UK
por: Kragh, Nana, et al.
Publicado: (2022)

PROTECT VIII Kids: BAY 94‐9027 (PEGylated Recombinant Factor VIII) safety and efficacy in previously treated children with severe haemophilia A
por: Santagostino, Elena, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_6nofijhensv9iodu7vsspqqng0